《新股表現》中免(01880.HK)續漲逾5%創新高 高盛首予H股目標價196元
內地最大免稅店集團及全球最大旅遊零售營運商中國中免(01880.HK)上週四(25日)以每股158元在港上市,高盛首予中免「買入」評級,H股目標價196元。該股繼上週五回升4%後,今天低開回落至162.1元獲承接,掉頭向上,接近中午收市升6.4%高見174.9元上市新高,現報173.4元,續升5.5%,成交191萬股,涉資3.23億元。
然而,中免A股(601888.SH)連續第二天受壓,今天股價高低見193.69元/189.01元人民幣,現報192.01元人民幣,反覆續跌0.2%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.